Evidence map›Paper›PMID 38664291›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2024

MAST® D72C test: a novel option for ESBL, AmpC and carbapenemase detection.

C C Noubam-Tchatat, E Maurin, S Proust, R Beyrouthy, R Bonnet, Frederic Robin

Abstract readEvaluation Study
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Comparison of three immunochromatographic assays for the rapid detection of CTX-M in Enterobacterales.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  3. Article
  4. AmpC β-lactamases detected in Southeast AsianJAC-antimicrobial resistance · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

C C Noubam-TchatatTeaching Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
E MaurinTeaching Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
S ProustTeaching Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
R BeyrouthyTeaching Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
R BonnetTeaching Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
Frederic RobinTeaching Hospital of Clermont-Ferrand, Clermont-Ferrand, France. frobin@chu-clermontferrand.fr.ORCID http://orcid.org/0000-0001-7304-5187
Inserm · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe MAST® D72C test is a phenotypical test which can detect ESBL and AmpC production in Enterobacterales. It can also identify the suspected presence of carbapenemase. The aim of the present study was to assess the sensitivity and specificity of this test and to discuss its usefulness in laboratories, especially those that use only an automated AST system.

methodThe performance of the MAST® D72C test was assessed against a collection of 119 non-redundant Enterobacterales isolates characterized for their content in β-lactamases, and compared with that of the reference double disk synergy test. β-lactamase content was established from phenotypic and genotypic analyses to collect a broad diversity of resistance mechanisms and bacterial strains, including 30 ESBL-producing strains, 32 strains overproducing chromosomal AmpC, 10 strains producing plasmid-encoded AmpC, 12 carbapenemase-producing strains, 13 strains combining the production of several β-lactamases, and 22 strains that produced other β-lactamases.

resultsThe sensitivity and specificity for ESBL-detection were comparable with those of the synergy test, 75 versus 72.5%, and 94.9 versus 93.7%, respectively. The sensitivity and specificity for AmpC-detection were 71.7% and 100%, respectively, and sensitivity reached 78.7% if we excluded carbapenem-resistant isolates. Carbapenemase-detection sensitivity was 90%.

conclusionThese results show that the MAST® D72C test can be a useful tool for the detection of ESBL- and AmpC-production in clinical laboratories.

Indexed as

Bacterial Proteinsbeta-LactamasesEnterobacteriaceaeSensitivity and SpecificityAnti-Bacterial AgentsEnterobacteriaceae InfectionsHumansMicrobial Sensitivity TestsAmpC beta-lactamasesAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseAmpCCarbapenemaseD72CEnterobacteralesESBLResistance

Identifiers

PMID38664291
OpenAlexW4395446401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.